Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,200 across all filing types
Latest filing 2021-04-12 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is an official letter addressed to stock exchanges regarding a regulatory compliance matter under SEBI Listing Regulations. It discusses the reclassification of a shareholder from 'Promoter Group' to 'Public' category and references prior intimation dates. The content is a formal notification of a corporate action related to shareholding classification, not a financial report, earnings release, or management discussion. The document length is short (1586 characters) and it is clearly an announcement or intimation to regulators rather than a detailed report. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-04-12 English
Allotment of Securities
Share Issue/Capital Change Classification · 100% confidence The document is a letter addressed to stock exchanges regarding the allotment of shares under the company's ESOP (Employee Stock Option Plan). It details the number of shares allotted, the increase in paid-up share capital, and confirms that the new shares rank equally with existing shares. There is no financial report, earnings data, or management discussion. The content is about a capital change event (share allotment). The document length is short (1257 characters), and it is an announcement of a share capital change, not a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2021-03-31 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding a request for the issuance of duplicate share certificates due to loss of original certificates. It references Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content includes details of shareholders, certificate numbers, and procedural notes about issuing duplicates. There is no financial data, earnings information, management discussion, or report publication mentioned. The document is an official regulatory announcement related to share certificate issuance and does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a regulatory filing informing stock exchanges about a corporate action related to share certificates. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 3265 characters, which is relatively short but contains substantive information about the share certificate issue, not just a report publication announcement.
2021-03-31 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated March 19, 2021, announcing a partnership between The Russian Direct Investment Fund (RDIF) and Stelis Biopharma Pvt Ltd to supply 200 million doses of the Sputnik V vaccine. It is addressed to stock exchanges and includes contact information and background on the companies involved. There are no financial statements, regulatory certifications, or detailed financial data. The document is a corporate announcement about a business partnership and product supply agreement, not a financial report, regulatory filing, or management report. It fits best as a general regulatory announcement or miscellaneous corporate news. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-19 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of a Series B and Series C fund raise totaling US$195 million by Stelis Biopharma, a division of Strides Pharma Science Limited. It details the amounts raised, investors involved, valuation post-funding, and intended use of proceeds. There is no financial statement or comprehensive financial report included, nor is this a transcript, regulatory filing, or management report. The content focuses on capital raising activities and financing updates. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7358 characters) and content confirm it is a full announcement rather than a brief notice or report publication announcement.
2021-03-19 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the voting results of a postal ballot. It references Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of voting results. The letter states that the resolution has been passed by the members with the requisite majority and encloses the voting results along with the scrutinizer's report. There is no indication of financial statements, management discussion, or other report content. The document is an official announcement of voting results from a shareholder vote, not the report or notice itself. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains detailed voting data, supporting a high confidence in classification.
2021-03-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.